Life Sciences and healthcare

An evolving regulatory landscape, along with a continuing wave of cross-border M&A activity, is transforming the life sciences and healthcare industry. Navigating new paths to growth during this era of transformation and risk presents complex challenges for industry leaders and start-ups, as well as their investors and capital providers. We can help.

Latest Insights, News, and Events

Latest Insights, News, and Events

Client Successes

Guided Supernus Pharmaceuticals and Galderma Laboratories to victory in the first-ever successful defense of a pharmaceutical patent in an inter partes review

Serve as lead counsel to a global pharmaceutical company across four continents in high-profile government investigations and internal reviews

Advised Merck & Co. on major cross-border M&A transactions including its strategic agreement with Quartet Medicine and its US$1.25B acquisition of Afferent Pharmaceuticals

Represented the lead arrangers in a US$900M bank financing for Bain Capital Private Equity's and J.H. Whitney Capital Partners' acquisition of Epic Health Services and PSA Healthcare.

A Recognized Leader

We bring a global, interdisciplinary approach to support our life sciences and healthcare clients’ complex, often mission-critical needs – from structuring transactions and financing arrangements, to developing first-of-its-kind innovative strategic partnerships and licensing arrangements, to protecting critical intellectual property, to resolving complicated U.S. healthcare and global anti-corruption enforcement matters, to providing the savvy compliance and legal counsel that keeps business moving forward. We partner with clients to understand and advise on their business and legal objectives delivering tailored solutions, innovative value-added offerings, and seamless service across practices and regions.

We advise eight of the 10 largest global pharmaceutical companies, as well as numerous emerging companies, healthcare providers and payors, and the investors and financial institutions that help bring their innovative ideas to life in markets across Asia, Europe, Latin America, and the United States. 


  • Our team of life sciences and healthcare lawyers includes former researchers, executives, and in-house counsel from leading life sciences companies. We understand the industry from our clients’ perspectives and ensure we are taking a client-focused approach.
  • We bring creative strategies to everything we do—from devising innovative solutions for getting deals done to proactively partnering with clients on compliance reviews to reduce anticorruption risks in jurisdictions around the world. Our lawyers handle complex transactional, regulatory, and litigation matters for leading organizations, providing guidance and insight into the industry as a whole.
  • We advise life sciences companies on all aspects of anti-corruption law: conducting global risk assessments; leading internal investigations and negotiating with the DOJ, SEC, and foreign prosecutors; designing and enhancing compliance programs; overseeing due diligence in transactions; and negotiating debarment and related sanctions with the US government, World Bank, and other development banks.
  • Our lawyers represent the largest life sciences companies in complex domestic and international matters. We have secured a long string of litigation victories on behalf of our clients, including success in numerous bet-the-company patent litigations and post-grant proceedings.


  • Recognized as Life Sciences Practice Group of the Year by Law360.
  • Named a Life Sciences Dealmaker of the Year by The American Lawyer and Finance Monthly.
  • Chambers USA highlights “The team is known as an international firm with a strong U.S. footprint and sector expertise in life sciences and frequently called upon for strategically significant cross-border transactions.”
  • Chair of our Life Sciences practice, Bruce Wexler was named Transatlantic Lawyer of the Year – IP by The American Lawyer.
  • Partner David Shine was named a Dealmaker of the Year by The American Lawyer for his work advising Merck on the US$14.2B sale of its consumer care business.
  • Recognized as Most Valuable Players – Life Sciences and IP by Law360.
  • Winner of Four Awards by LMG Life Sciences including General Patent Litigator of the Year (New York), Post Grant Proceedings Attorney of the Year, and Two Impact Hatch-Waxman Cases of the Year.
  • Ranked in consecutive editions of Global Investigations Review GIR 100, for handling sophisticated cross-border government-led and internal investigations.